Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Accounts Payables (2020 - 2025)

Candel Therapeutics' Accounts Payables history spans 4 years, with the latest figure at $422000.0 for Q4 2023.

  • On a quarterly basis, Accounts Payables rose 11.05% to $422000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $422000.0, a 11.05% increase, with the full-year FY2023 number at $422000.0, up 11.05% from a year prior.
  • Accounts Payables hit $422000.0 in Q4 2023 for Candel Therapeutics, up from $250000.0 in the prior quarter.
  • Over the last five years, Accounts Payables for CADL hit a ceiling of $1.6 million in Q4 2021 and a floor of $250000.0 in Q3 2023.
  • Historically, Accounts Payables has averaged $854916.7 across 4 years, with a median of $840000.0 in 2020.
  • The widest YoY moves for Accounts Payables: up 108.7% in 2022, down 76.1% in 2022.
  • Tracing CADL's Accounts Payables over 4 years: stood at $921000.0 in 2020, then skyrocketed by 72.64% to $1.6 million in 2021, then tumbled by 76.1% to $380000.0 in 2022, then rose by 11.05% to $422000.0 in 2023.
  • Business Quant data shows Accounts Payables for CADL at $422000.0 in Q4 2023, $250000.0 in Q3 2023, and $480000.0 in Q2 2023.